NEW DELHI: Two doses of Covaxin are 50 per cent effective against symptomatic COVID-19, according to the first real-world assessment of India’s indigenous Coronavirus vaccine published in The Lancet Infectious Diseases journal.
The results of an interim study recently published in The Lancet showed that two doses of Covaxin, also known as BBV152, had 77.8 per cent efficacy against symptomatic disease and present no serious safety concerns.
The latest study assessed 2,714 hospital workers at the All India Institute of Medical Sciences (AIIMS) in Delhi, from April 15 May 15, who were symptomatic and underwent RT-PCR test for COVID-19 detection.
Researchers noted that the Delta variant was the dominant strain in India during the study period, accounting for approximately 80 per cent of all confirmed COVID-19 cases.
Covaxin, developed by Hyderabad-based Bharat Biotech in collaboration with the National Institute of Virology, Indian Council of Medical Research (NIV-ICMR), Pune, is an inactivated whole virus vaccine administered in a two-dose regimen, 28 days apart.
In January this year, Covaxin was approved for emergency use in India for people aged 18 and above. The World Health Organization (WHO) added the vaccine to its list of approved emergency use COVID-19 vaccines earlier this month.
Esta historia es de la edición November 25, 2021 de Millennium Post Delhi.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 8500 revistas y periódicos.
Ya eres suscriptor ? Conectar
Esta historia es de la edición November 25, 2021 de Millennium Post Delhi.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 8500 revistas y periódicos.
Ya eres suscriptor? Conectar
India, the biggest promotor of T20 cricket, determined to end World Cup title drought
After winning inaugural T20]1 in SA in 2007, India has only reached one more final in 2014
IPL final: Sunrisers big-hitters up against Rajasthan's spin stars in 'battle of nerves'
IPL's best power hitters Travis Head and Abhishek Sharma will face a very different challenge in wily spin twins Yuzvendra Chahal and Ravichandran Ashwin when Sunrisers Hyderabad take on Rajasthan Royals in a high-octane second Qualifier here on Friday.
When chips were down, we started to play for our self-respect: Kohli
Fighting for self-respect when everything seemed lost propelled Royal Challengers Bengaluru to six consecutive victories and earned them a place in the IPL 2024 Eliminator, said Virat Kohli after the side's winning streak was ended by Rajasthan Royals.
Doesn't exactly fit into my lifestyle, says Ponting
TURNS DOWN INDIA HEAD COACH APPROACH
CII at forefront of Bengal’s industrial advancement across various sectors
In a significant stride to enable MSMEs leverage the benefit of digital tools, CII with its Project Digital Saksham in partnership with Mastercard center for Inclusive Growth is working in 13 States and across 55 clusters.
AI-based optimisations: Paytm expects annual saving of up to ₹500 cr
Paytm has been at the forefront of leveraging AI to streamline its business processes, optimise risk management
Al-based optimisations: Paytm expects annual saving of up to 500 cr
Paytm has been at the forefront of leveraging AI to streamline its business processes, optimise risk management
CII at forefront of Bengal’s industrial advancement across various sectors
In a significant stride to enable MSMEs leverage the benefit of digital tools, CII with its Project Digital Saksham in partnership with Mastercard center for Inclusive Growth is working in 13 States and across 55 clusters.
India to get rating support if it uses RBI dividend to cut fiscal deficit: S@P analyst
India can get 'rating support' over time if it utilises the highest-ever dividend of over Rs 2 lakh crore received from the Reserve Bank to reduce fiscal deficit, said an S&P Global Rating analyst on Thursday.
ITC posts Q4 profit of ₹5,191 crore, revenue climbs 2% to ₹19,446 crore
The company had logged a net profit of Rs 5,242.59 crore in the same period of the previous fiscal, ITC said in a regulatory filing